Halma acquires MK Test, bringing new opportunities for growth

Halma plc

Halma plc (LON:HLMA), the global group of life-saving technology companies, has announced that it has acquired MK Test Systems Limited.

Founded in 1990 and headquartered in Wellington, Somerset, UK, MK Test designs and manufactures safety-critical electrical testing technology. Its products are used globally to test the integrity of high voltage electrical systems in aerospace, rail and commercial EV industries.

The cash consideration for MK Test is £44m, on a cash- and debt-free basis, to be funded from Halma’s existing facilities. MK Test’s unaudited revenue for the 12 months to March 2024 was £12.4m, with Return on Sales substantially above the upper end of Halma’s target range of 18-22%. MK Test will be a standalone company within Halma’s Safety sector, led by its current management team.

Marc Ronchetti, Group Chief Executive of Halma, commented:

“MK Test further enhances our capabilities in electrical safety and brings new opportunities for growth, driven by increasing safety regulation and the need to protect high value assets. Its technology plays an important role in automated electrical testing and in ensuring the integrity of electrical systems. We are delighted to welcome MK Test and to support its development as it continues to scale its business globally.”

Jason Evans, Managing Director of MK Test, said:

“Passenger and operator safety is a top priority for our customers. They must ensure that platforms and machines with increasingly complex electrical systems are manufactured and assembled correctly, are operating within specification, and are being properly maintained. Joining Halma means we can grow our business in key markets while helping more businesses meet increasing safety regulations and demands for test traceability. MK Test Systems is aligned with Halma’s purpose of growing a safer, cleaner, healthier future for everyone, every day.”

Share on:
Find more news, interviews, share price & company profile here for:

    Nuformix applies for US Orphan Drug Designation for NXP002 in IPF

    Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis.

    Dekel Agri-Vision sees record cashew output, higher palm oil prices

    Dekel Agri-Vision has announced a July 2025 update, highlighting record monthly raw cashew nut processing of 533 tonnes at its Tiebissou plant, up 423% from July 2024.

    Diversified Energy delivers strong H1 2025 with Carlyle partnership boost

    Diversified Energy Company posted first-half 2025 results in line with expectations, delivering strong production growth, improved financial metrics, and $152 million in adjusted free cash flow

    EDX Medical Group to complete the development of new pneumonia test

    EDX Medical will partner with the Intensive Care Unit at Cambridge University Hospitals NHS Foundation Trust to support the further advancement of a highly precise test that identifies the DNA or RNA of the microbes that cause lung infection in critically ill patients. 

    Union Jack Oil director increases shareholding

    Union Jack Oil Non-Executive Director Craig Howie has acquired 122,000 shares at 5.075 pence each, raising his total holding to 3,377,000 shares, representing 2.21% of the company’s issued share capital.

    Aptamer Group to host technical development update webinar

    Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes.

      Search

      Search